OncoMethylome Sciences (BE) - OncoMethylome Sciences Reinforces U.S. Presence with Key Executive Appointments

OncoMethylome Sciences (BE) - OncoMethylome Sciences Reinforces U.S. Presence with Key Executive Appointments

DURHAM, NC, and LIEGE, BELGIUM - September 28, 2010 - OncoMethylome Sciences SA (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA) today announced the appointments of Dr. Melissa A. Thompson as Vice President Regulatory Affairs and Quality Assurance, and of Mr. Christopher (Chris) Thibodeau as Vice President Commercial Operations.

Dr. Jan Groen, Chief Executive Officer of OncoMethylome, said: "With extensive experience in the molecular diagnostics space in the U.S., Melissa and Chris will be instrumental in expanding our presence in the U.S. market. They will both play a key role in developing and executing our new strategy, providing invaluable knowledge of the regulatory and commercialization processes. "

Melissa A. Thompson, PhD, MBA, CT (ASCP), VP Regulatory Affairs & Quality Assurance Melissa has more than 25 years of experience in the pharmaceutical, medical device, and molecular diagnostics industries. She has provided extensive consultative services in diagnostics to leading companies such as Johnson & Johnson, Wyeth, Inverness, and Affymetrix, as well start-ups like Signature Genomic Laboratories, Prognomix, Allegro Diagnostics, and ExonHit Therapeutics. She has fostered multiple products through U.S. Food and Drug Administration approval, and has additional background in clinical research and clinical trial design.

Melissa Thompson holds a Ph.D. in Organizational Management from Concordia University and an MBA from Temple University, Philadelphia, PA.

Christopher Thibodeau, VP Commercial Operations Chris brings over 15 years of sales, marketing and commercial leadership experience in the diagnostics arena. As Vice President Commercial Operations, he is responsible for developing and executing OncoMethylome's key strategic sales & marketing and business development initiatives. Prior to joining OncoMethylome he served as Senior Director of Marketing at Agendia Inc., Vice President of Sales and Marketing for Numira Biosciences, National Director of Sales US LABS (an industry leader in cancer diagnostic and genomic testing services); and a number of sales and marketing management roles at Ventana Medical.

Chris Thibodeau holds a BSc degree from the East Stroudsburg University in Pennsylvania and studied French at the Faculté des Lettres in Nancy, France.

 

About OncoMethylome Sciences

OncoMethylome Sciences is a leading molecular diagnostics company that commercializes and develops cancer-screening tests to assist physicians in detecting and treating cancer early. The company's tests are based on proprietary gene methylation technology invented at Johns Hopkins University and are designed to aid the physician detect early stages of cancer development, predict a patient's response to drug therapy, and predict the likelihood of cancer recurrence. OncoMethylome Sciences collaborates with leading cancer research centers, such as Johns Hopkins, in Baltimore, MD, and has a number of commercial and collaborative partnerships with LabCorp, Schering-Plough, GlaxoSmithKline Biologicals, Millipore Corporation's BioScience Division, Roche, Merck KGaA and Qiagen.

 

For more information:

Dr. Jan Groen

CEO

+32 4.364.20.70 office

[email protected]

 

This press release contains forward-looking statements and estimates with respect to the anticipated future performance of OncoMethylome and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the Company's control, and may turn out to be materially different.

 

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.